Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB25FDL52
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $98,275
Award facts
- Contract value 100% obligated
- $98,274.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $98,274.72 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 4, 2025, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. This delivery order, with an ultimate completion date of September 25, 2025, represents a direct fulfillment under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at $499.999 billion through November 2026. The contract carries no set-aside designation, allowing the woman-owned small business to compete on an unrestricted basis within the SPE2DB program framework, which enables DLA to procure pharmaceutical products supporting military health facilities nationwide.
DMS Pharmaceutical Group Inc., based in Park Ridge, Illinois, serves as a critical pharmaceutical distributor within the federal supply chain, specializing in branded and generic prescription drugs, biologics, and medical consumables for Department of Defense healthcare systems. As a woman-owned small business established in 2001, the company has built a substantial portfolio of pharmaceutical delivery orders covering oncology treatments, specialty medications, and injectable products. This particular delivery order for Keytruda, an oncology immunotherapy medication, aligns with DMS Pharmaceutical Group's demonstrated expertise in supplying advanced pharmaceutical therapies to military medical facilities across the United States.
Quick answers
Who was awarded contract SPE2DB25FDL52?
SPE2DB25FDL52 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 4, 2025.
How much is contract SPE2DB25FDL52 worth?
The government has obligated $98,275 on SPE2DB25FDL52.
Is contract SPE2DB25FDL52 an order under another contract?
Yes. SPE2DB25FDL52 is a delivery order under SPE2DB22D9239, an indefinite delivery contract.
Was contract SPE2DB25FDL52 competed?
The extent of competition for SPE2DB25FDL52 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award